#Sweden #Stockholm #Eisai #Leqembi #BioArctic

BioArctic's Nomination Committee for 2027

In a recent announcement, BioArctic AB (publ), traded on Nasdaq Stockholm under the ticker BIOA B, has revealed the composition of its Nomination Committee for the upcoming Annual General Meeting scheduled for May 27, 2027. The Nomination Committee is crucial as it plays a key role in preparing proposals relating to the election of Board members and other significant agenda items for shareholder approval.

Composition of the Nomination Committee

The newly appointed Nomination Committee includes representatives from three of the largest shareholders based on voting rights as of September 30, 2026, along with the Chair of the Board, designated as the convener of this committee. The members include:

• - Margareta Öhrvall, appointed by Demban AB
• - Pär Gellerfors, appointed by Ackelsta AB
• - Thomas Ehlin, the Chair of the Nomination Committee, who represents Fjärde AP-fonden

This collective not only reflects substantial diversity in representation but also holds a significant stake in the company, controlling approximately 57% of the shares and an impressive 82% of voting rights. This alignment ensures that the interests of a majority of shareholders are well-represented in the decision-making processes leading up to the AGM.

Instructions for Shareholders

BioArctic has provided clear guidance on how shareholders can engage with the Nomination Committee. Shareholders seeking to propose candidates or submit suggestions can do so by email to [email protected] (with 'Nomination Committee' in the subject line) or by post to BioArctic AB, Attn: Nomination Committee, Warfvinges väg 35, SE-112 51 Stockholm, Sweden. In order to be considered, all proposals must be submitted by January 15, 2027.

The committee's recommendations and proposals will be published before the General Meeting, and further details are accessible on BioArctic’s official website, where transparency in governance is emphasized.

Importance of the AGM

The Annual General Meeting, scheduled for 4:30 PM CEST on May 27, 2027, is not just a routine gathering but a vital opportunity for shareholders to make their voices heard and influence corporate governance at BioArctic. Shareholders wishing to have specific matters discussed during the AGM must submit their requests no later than April 15, 2027.

About BioArctic

BioArctic AB is a notable entity in the biopharmaceutical sector, dedicated to tackling neurodegenerative diseases through innovative therapeutics. Among its key achievements is the development of Leqembi® (lecanemab), the world's first drug shown to successfully slow cognitive decline in early Alzheimer's disease, developed in collaboration with Eisai. The company also boasts a robust research portfolio targeting Parkinson’s disease and ALS, leveraging advanced technologies to enhance the delivery and efficacy of treatments.

BioArctic maintains a position on Nasdaq Stockholm’s Large Cap segment, reflecting its significant market presence and commitment to scientific advancement. For further inquiries regarding the Nomination Committee or corporate operations, stakeholders are encouraged to reach out to:

• - Oskar Bosson, Chief Investor Relations and Communications Officer, at [email protected], phone: +46 704 107 180.
• - Jenny Ljunggren, External Communications and Investor Relations Manager, at [email protected], phone: +46 76 013 86 08.

For more information, please visit BioArctic's official website at www.bioarctic.com.